Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Other Non-Current Liabilities (2017 - 2025)

Aclaris Therapeutics has reported Other Non-Current Liabilities over the past 9 years, most recently at $11.0 million for Q4 2025.

  • Quarterly results put Other Non-Current Liabilities at $11.0 million for Q4 2025, up 26.44% from a year ago — trailing twelve months through Dec 2025 was $11.0 million (up 26.44% YoY), and the annual figure for FY2025 was $11.0 million, up 26.44%.
  • Other Non-Current Liabilities for Q4 2025 was $11.0 million at Aclaris Therapeutics, up from $10.6 million in the prior quarter.
  • Over the last five years, Other Non-Current Liabilities for ACRS hit a ceiling of $33.1 million in Q4 2022 and a floor of $1.6 million in Q3 2022.
  • Median Other Non-Current Liabilities over the past 5 years was $7.4 million (2023), compared with a mean of $11.1 million.
  • Biggest five-year swings in Other Non-Current Liabilities: surged 1884.13% in 2023 and later tumbled 93.09% in 2024.
  • Aclaris Therapeutics' Other Non-Current Liabilities stood at $2.2 million in 2021, then surged by 1423.94% to $33.1 million in 2022, then crashed by 81.27% to $6.2 million in 2023, then surged by 40.32% to $8.7 million in 2024, then rose by 26.44% to $11.0 million in 2025.
  • The last three reported values for Other Non-Current Liabilities were $11.0 million (Q4 2025), $10.6 million (Q3 2025), and $10.5 million (Q2 2025) per Business Quant data.